MRUS

Merus N.V. (MRUS) | Rumor.io

Merus

MRUS

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)100%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about MRUS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% +0	0% 0

Sep 30

Merus N.V. ($MRUS) is expected to be acquired by Genmab for $8 billion in cash, with the deal having divided analysts on its merits.
The acquisition is seen as a positive for Genmab, filling a gap in its royalty streams, but some analysts believe the price paid was too high.
Several analysts have updated their ratings on Merus, with some setting target prices of $97 or higher, while others remain cautious or neutral.

Generated by AI

Sentiment

Of the messages about MRUS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	90.05% -2.56
Bearish	—	—	0% 0	9.95% +2.56

Bullish· Sep 29

The acquisition of MRUS by GMAB is expected to be accretive to EBITDA by the end of 2029.
The buyout price of $97 per share represents a 41% premium to MRUS's recent levels.
The acquisition of MRUS brings in petosemtamab, a late-stage cancer drug with 2 FDA breakthrough designations, which is expected to drive growth and potentially launch by 2027.

Bearish· Oct 7

$MRUS is likely to close below $25 tomorrow.
The stock's price is expected to drop to $22-24 by the end of the day if the volume of trading does not increase.
The company's market capitalization has increased by $350 million, which is considered unrealistic and unsustainable, leading to a predicted price drop to around $20.

Generated by AI

Topics

Of the messages about MRUS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	0%	0%	0%	5.22%
Announcements	100%	100%	100%	87.72%
Controversies	0%	0%	0%	0.99%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	0.76%
Technical Analysis	0%	0%	0%	5.31%

Earnings· Apr 26

$MRUS Reports Q4 EPS loss of €0.73 and revenue of €3.82M
$MRUS to host Q4 Earnings Call TODAY at 8:30 AM Eastern, stream live or on replay
$MRUS Reports Q4 EPS loss of €0.73 and revenue of €3.82M

Analysts· Jun 7

Citigroup upgraded Merus N.V. (MRUS) to Buy from Neutral with a new price target of $31.
Analyst Yigal Nochomovitz at Citigroup raised the price target for MRUS from $24 to $31.
The upgrade is a bullish sentiment for MRUS, indicating potential growth and increased investor interest.

Announcements· Sep 29

Genmab is acquiring Merus N.V. for $97 per share in an all-cash transaction worth approximately $8.0 billion.
The acquisition is expected to expand Genmab's late-stage pipeline and accelerate its transition into a wholly-owned model.
Genmab expects the acquisition to be accretive to EBITDA by the end of 2029 and potentially lead to a stock doubling event for Merus.

Generated by AI

Community

Of the messages about MRUS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	100%	58.66%
Newcomers	0%	0%	0%	41.34%

Regulars· Sep 29

Merus N.V. ($MRUS) is being acquired by Genmab for $97.00 per share in an all-cash transaction valued at approximately $8.0 billion.
The acquisition is expected to be accretive to Genmab's EBITDA by the end of 2029, and Merus' peak sales are predicted to exceed those of Senesco Technologies ($SGEN).
The acquisition price of $97.00 per share represents a significant increase from Merus' August 28 closing price of $68.50, with some investors predicting a stock doubling event.

Newcomers· Sep 29

$MRUS has been acquired by Genmab (GMAB) for $8 billion, with the deal worth $97 per share.
The acquisition is expected to boost Genmab's growth, with a potential drug launch by 2027, and the petosemtamab cancer drug has 2 FDA breakthrough designations.
The $MRUS data presented at ASCO was stellar, and if bought after the data was presented, the stock would be up 63%, with the deal bringing in a late-stage cancer drug.

Generated by AI

Also Discussed

Investors talking about MRUS also mention

#	Name	Attention
1	Genmab A/S American Depositary SharesGMAB	0%0
2	BPMC - Blueprint Medicines Corporation	——
3	Bicycle Therapeutics plc - ADRBCYC	0%0
4	PDS Biotechnology CorporationPDSB	0%-0.01
5	argenx SE American Depositary ReceiptARGX	0%0
6	ALX Oncology Holdings Inc.ALXO	0%0
7	AFMD - Affimed N.V.	——
8	Kura Oncology, Inc.KURA	0%+0
9	LVTX - LAVA Therapeutics N.V.	——
10	SWTX - SpringWorks Therapeutics, Inc.	——

Merus N.V.

Location

Social

What share of all stock conversation is about MRUS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% +0	0% 0

Sep 30

Merus N.V. ($MRUS) is expected to be acquired by Genmab for $8 billion in cash, with the deal having divided analysts on its merits.
The acquisition is seen as a positive for Genmab, filling a gap in its royalty streams, but some analysts believe the price paid was too high.
Several analysts have updated their ratings on Merus, with some setting target prices of $97 or higher, while others remain cautious or neutral.

Generated by AI

Sentiment

Of the messages about MRUS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	90.05% -2.56
Bearish	—	—	0% 0	9.95% +2.56

Bullish· Sep 29

The acquisition of MRUS by GMAB is expected to be accretive to EBITDA by the end of 2029.
The buyout price of $97 per share represents a 41% premium to MRUS's recent levels.
The acquisition of MRUS brings in petosemtamab, a late-stage cancer drug with 2 FDA breakthrough designations, which is expected to drive growth and potentially launch by 2027.

Bearish· Oct 7

$MRUS is likely to close below $25 tomorrow.
The stock's price is expected to drop to $22-24 by the end of the day if the volume of trading does not increase.
The company's market capitalization has increased by $350 million, which is considered unrealistic and unsustainable, leading to a predicted price drop to around $20.

Generated by AI

Topics

Of the messages about MRUS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	0%	0%	0%	5.22%
Announcements	100%	100%	100%	87.72%
Controversies	0%	0%	0%	0.99%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	0.76%
Technical Analysis	0%	0%	0%	5.31%

Earnings· Apr 26

$MRUS Reports Q4 EPS loss of €0.73 and revenue of €3.82M
$MRUS to host Q4 Earnings Call TODAY at 8:30 AM Eastern, stream live or on replay
$MRUS Reports Q4 EPS loss of €0.73 and revenue of €3.82M

Analysts· Jun 7

Citigroup upgraded Merus N.V. (MRUS) to Buy from Neutral with a new price target of $31.
Analyst Yigal Nochomovitz at Citigroup raised the price target for MRUS from $24 to $31.
The upgrade is a bullish sentiment for MRUS, indicating potential growth and increased investor interest.

Announcements· Sep 29

Genmab is acquiring Merus N.V. for $97 per share in an all-cash transaction worth approximately $8.0 billion.
The acquisition is expected to expand Genmab's late-stage pipeline and accelerate its transition into a wholly-owned model.
Genmab expects the acquisition to be accretive to EBITDA by the end of 2029 and potentially lead to a stock doubling event for Merus.

Generated by AI

Community

Of the messages about MRUS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	100%	58.66%
Newcomers	0%	0%	0%	41.34%

Regulars· Sep 29

Merus N.V. ($MRUS) is being acquired by Genmab for $97.00 per share in an all-cash transaction valued at approximately $8.0 billion.
The acquisition is expected to be accretive to Genmab's EBITDA by the end of 2029, and Merus' peak sales are predicted to exceed those of Senesco Technologies ($SGEN).
The acquisition price of $97.00 per share represents a significant increase from Merus' August 28 closing price of $68.50, with some investors predicting a stock doubling event.

Newcomers· Sep 29

$MRUS has been acquired by Genmab (GMAB) for $8 billion, with the deal worth $97 per share.
The acquisition is expected to boost Genmab's growth, with a potential drug launch by 2027, and the petosemtamab cancer drug has 2 FDA breakthrough designations.
The $MRUS data presented at ASCO was stellar, and if bought after the data was presented, the stock would be up 63%, with the deal bringing in a late-stage cancer drug.

Generated by AI

Merus

Social

Sep 30

Sentiment

Bullish· Sep 29

Bearish· Oct 7

Topics

Earnings· Apr 26

Analysts· Jun 7

Announcements· Sep 29

Community

Regulars· Sep 29

Newcomers· Sep 29

Also Discussed

Merus N.V.

Company Information

Location

Social

Sep 30

Sentiment

Bullish· Sep 29

Bearish· Oct 7

Topics

Earnings· Apr 26

Analysts· Jun 7

Announcements· Sep 29

Community

Regulars· Sep 29

Newcomers· Sep 29

Also Discussed